<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463683</url>
  </required_header>
  <id_info>
    <org_study_id>V232-062</org_study_id>
    <nct_id>NCT01463683</nct_id>
  </id_info>
  <brief_title>Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)</brief_title>
  <official_title>A Study in Healthy Japanese Young Adults to Assess the Safety, Tolerability, and Immunogenicity of HEPTAVAX-II Manufactured Using a Modified Process</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II
      compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2XP HEPTAVAX™-II is manufactured using a modified process in which the composition of the
      amorphous aluminum hydroxyphosphate sulfate adjuvant has been modified by increasing the
      phosphate content by approximately 2-fold. Thus the modified process HEPTAVAX™-II is referred
      to as 2XP HEPTAVAX™-II.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection</measure>
    <time_frame>Month 7</time_frame>
    <description>Blood samples were collected for anti-hepatitis B antibody assays. Seroprotection was defined as ≥10 mIU/mL anti-hepatitis B antibody.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Injection-site Adverse Events</measure>
    <time_frame>Up to 15 days after each vaccination</time_frame>
    <description>Participants were evaluated for injection-site adverse events using MedDRA version 15.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Pyrexia Adverse Events</measure>
    <time_frame>Up to 15 days after each vaccination</time_frame>
    <description>Participants were evaluated for pyrexia adverse events using MedDRA version 15.1. Pyrexia (fever) was defined as an oral temperature ≥37.8°C ( ≥100.0°F).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">722</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>V232-2XP SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V232-1XP SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V232-2XP IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2XP HEPTAVAX™-II SC</intervention_name>
    <arm_group_label>V232-2XP SC</arm_group_label>
    <other_name>RECOMBIVAX HB</other_name>
    <other_name>HBVAXPRO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1XP HEPTAVAX™-II SC</intervention_name>
    <arm_group_label>V232-1XP SC</arm_group_label>
    <other_name>RECOMBIVAX HB</other_name>
    <other_name>HBVAXPRO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2XP HEPTAVAX™-II IM</intervention_name>
    <arm_group_label>V232-2XP IM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To receive the first study vaccination, Participants should meet all inclusion criteria.

          -  Participants provide written informed consent for the trial. The Participant may also
             provide consent for Future Biomedical Research. However, the Participant may
             participate in the main trial without participating in Future Biomedical Research.

          -  Participant is Japanese male or female, between 20 to 35 years of age on the day of
             the first study vaccination.

          -  Participant is determined to be in general good health based on the medical history
             taken on Day 1 prior to receiving the first injection of the vaccine. Any underlying
             chronic illness must be documented to be in stable condition.

          -  For females, a negative urine pregnancy test just prior to vaccination on Day 1.

        Exclusion Criteria:

        To receive the first study vaccination, Participants should not have any exclusion
        criteria. For items with an asterisk (*), if the Participant meets these exclusion
        criteria, the visit may be rescheduled for a time when these criteria are not met.

          -  Participant has a history of previous hepatitis B infection.

          -  Participant has a history of vaccination with any hepatitis B vaccine.

          -  *Participant has a recent (≤72 hours) history of febrile illness (oral temperature ≥
             37.8°C).

          -  Participant has a known or suspected hypersensitivity to any component of HEPTAVAX™-II
             vaccine and latex (e.g., aluminum, yeast).

          -  Participant has a recent administration (within 3 months prior to first injection with
             the study vaccine) of hepatitis B immune globulin (HBIG), serum immune globulin, or
             any other blood-derived product, or is expected to require such blood-derived products
             during the study.

          -  *Participant has received licensed inactivated vaccines within 14 days prior or
             licensed live vaccines within 28 days prior to first injection with the study vaccine.

          -  Participant has received investigational drugs or other investigational vaccines
             within 3 months prior to first injection with the study vaccine.

          -  Use of immunosuppressive therapy. Participants on corticosteroids should be excluded
             if they are receiving or are expected to receive, in the period from 4 weeks prior to
             enrollment until 6 weeks post vaccination, systemic doses greater than required for
             physiological replacement, i.e., &gt;5 mg of prednisone (or equivalent) per day for &gt;2
             weeks (except for use of topical or inhalation steroid therapy).

          -  Pregnant women, nursing mothers, and women planning to become pregnant within the
             study period. Women of childbearing age should employ an acceptable method of
             contraception during the study (e.g., condom, diaphragm, oral contraceptive,
             Intrauterine Device (IUD), or hormonal implants are considered acceptable).

          -  Participant has any condition, which, in the opinion of the investigator, might
             interfere with the evaluation of the study objectives.

          -  Participant has a coagulation disorder contraindicating intramuscular injection.

          -  Participant has immunocompromised condition (such as Human Immunodeficiency Virus
             (HIV) positive, leukemia, lymphoma, other cancers or disorders).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2011</study_first_posted>
  <results_first_submitted>October 9, 2013</results_first_submitted>
  <results_first_submitted_qc>December 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2014</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>V232-2XP Subcutaneous (SC)</title>
          <description>2XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P2">
          <title>V232-1XP SC</title>
          <description>1XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P3">
          <title>V232-2XP Intramuscular (IM)</title>
          <description>2XP HEPTAVAX™-II vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="309"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 1 (Day 1)</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="308"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 2 (Month 1)</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 3 (Month 6)</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="281"/>
                <participants group_id="P3" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="278"/>
                <participants group_id="P3" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>V232-2XP SC</title>
          <description>2XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B2">
          <title>V232-1XP SC</title>
          <description>1XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B3">
          <title>V232-2XP IM</title>
          <description>2XP HEPTAVAX™-II vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="309"/>
            <count group_id="B2" value="308"/>
            <count group_id="B3" value="104"/>
            <count group_id="B4" value="721"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="4.7"/>
                    <measurement group_id="B2" value="26.8" spread="4.6"/>
                    <measurement group_id="B3" value="26.9" spread="4.9"/>
                    <measurement group_id="B4" value="27.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="361"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection</title>
        <description>Blood samples were collected for anti-hepatitis B antibody assays. Seroprotection was defined as ≥10 mIU/mL anti-hepatitis B antibody.</description>
        <time_frame>Month 7</time_frame>
        <population>The per protocol population consisted of all randomized participants who met enrollment criteria, did not violate the protocol, were seronegative at Baseline, and had vaccination and blood collection. Seroprotection was evaluated only for participants receiving vaccine subcutaneously; intramuscular vaccination was evaluated for safety only.</population>
        <group_list>
          <group group_id="O1">
            <title>V232-2XP SC</title>
            <description>2XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>V232-1XP SC</title>
            <description>1XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection</title>
          <description>Blood samples were collected for anti-hepatitis B antibody assays. Seroprotection was defined as ≥10 mIU/mL anti-hepatitis B antibody.</description>
          <population>The per protocol population consisted of all randomized participants who met enrollment criteria, did not violate the protocol, were seronegative at Baseline, and had vaccination and blood collection. Seroprotection was evaluated only for participants receiving vaccine subcutaneously; intramuscular vaccination was evaluated for safety only.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1"/>
                    <measurement group_id="O2" value="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Incidence of seroprotection with V232-2XP SC is non-inferior to V232-1XP SC if the lower bound of the 95% confidence interval of the difference is greater than -10%</non_inferiority_desc>
            <param_type>Difference in percentage of participants</param_type>
            <param_value>7.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Injection-site Adverse Events</title>
        <description>Participants were evaluated for injection-site adverse events using MedDRA version 15.1</description>
        <time_frame>Up to 15 days after each vaccination</time_frame>
        <population>All randomized participants who received at least 1 vaccination were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>V232-2XP SC</title>
            <description>2XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>V232-1XP SC</title>
            <description>1XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>V232-2XP IM</title>
            <description>2XP HEPTAVAX™-II vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Injection-site Adverse Events</title>
          <description>Participants were evaluated for injection-site adverse events using MedDRA version 15.1</description>
          <population>All randomized participants who received at least 1 vaccination were included in the analysis</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.162</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in percentage of participants</param_type>
            <param_value>4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in percentage of participants</param_type>
            <param_value>11.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>21.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.246</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in percentage of participants</param_type>
            <param_value>6.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>16.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Pyrexia Adverse Events</title>
        <description>Participants were evaluated for pyrexia adverse events using MedDRA version 15.1. Pyrexia (fever) was defined as an oral temperature ≥37.8°C ( ≥100.0°F).</description>
        <time_frame>Up to 15 days after each vaccination</time_frame>
        <population>All randomized participants who received at least 1 vaccination were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>V232-2XP SC</title>
            <description>2XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>V232-1XP SC</title>
            <description>1XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>V232-2XP IM</title>
            <description>2XP HEPTAVAX™-II vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pyrexia Adverse Events</title>
          <description>Participants were evaluated for pyrexia adverse events using MedDRA version 15.1. Pyrexia (fever) was defined as an oral temperature ≥37.8°C ( ≥100.0°F).</description>
          <population>All randomized participants who received at least 1 vaccination were included in the analysis</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.659</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in percentage of participants</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.459</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in percentage of participants</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.7</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.686</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in percentage of participants</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events: up to Month 7; non-serious adverse events: up to 14 days after each vaccination</time_frame>
      <desc>The analysis population for adverse events was participants who received at least 1 vaccination</desc>
      <group_list>
        <group group_id="E1">
          <title>V232-2XP SC</title>
          <description>2XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E2">
          <title>V232-1XP SC</title>
          <description>1XP HEPTAVAX™-II vaccine 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E3">
          <title>V232-2XP IM</title>
          <description>2XP HEPTAVAX™-II vaccine 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="239" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="294" subjects_affected="172" subjects_at_risk="309"/>
                <counts group_id="E2" events="288" subjects_affected="152" subjects_at_risk="308"/>
                <counts group_id="E3" events="40" subjects_affected="26" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="441" subjects_affected="216" subjects_at_risk="309"/>
                <counts group_id="E2" events="400" subjects_affected="194" subjects_at_risk="308"/>
                <counts group_id="E3" events="120" subjects_affected="62" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Injection-site pruritus</sub_title>
                <counts group_id="E1" events="75" subjects_affected="50" subjects_at_risk="309"/>
                <counts group_id="E2" events="81" subjects_affected="54" subjects_at_risk="308"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="278" subjects_affected="165" subjects_at_risk="309"/>
                <counts group_id="E2" events="253" subjects_affected="149" subjects_at_risk="308"/>
                <counts group_id="E3" events="39" subjects_affected="26" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="309"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="308"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="309"/>
                <counts group_id="E2" events="28" subjects_affected="20" subjects_at_risk="308"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

